Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

TEM.NASDAQ

Tempus AI, Inc. Common Stock

Healthcare | Health Information Services

AI-enabled precision medicine company combining diagnostics, clinical data, and analytics to improve oncology and broader care decisions.

Flagship Insight

Why the Market Misprices This Biological Data Moat Under Restrictive Rates

There is sharp divergence across reports regarding this asset's valuation sustainability, though high consensus exists on its formidable clinical data moat. While geopolitical decoupling acts as a primary driver, persistent cash burn and high leverage remain the central risks threatening near-term performance under restrictive monetary conditions.

Forecast TimelineUpdated On Jul 02 2026

Tempus AI, Inc. Common Stock (TEM) Stock Forecast and AI Rating

Recommendation

Hold & Monitor

Model signals are balanced; wait for clearer evidence.

2027

1-Year

NEUTRAL

$62

+2.7%

+24% IF INCL. DIVS

2029

3-Year

N/A

$90

+83%

2031

5-Year

NEUTRAL

$123

+105%

+152% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

This asset presents a highly polarized setup, balancing an unassailable clinical-genomic data moat against severe balance sheet leverage and cash burn. The core thesis hinges on the rapid mix-shift toward high-margin data licensing and AI modeling, which is expected to drive operating leverage and push the company toward free cash flow neutrality by late 2027 or 2028. While the geopolitical tailwinds of the BIOSECURE Act structurally insulate domestic market share, the restrictive macroeconomic regime and elevated discount rates will continue to compress valuation multiples, demanding flawless operational execution.

Key insights

High-margin data licensing and AI platform scaling act as the primary engines for gross margin expansion.
The BIOSECURE Act serves as a powerful regulatory barrier, redirecting domestic biopharma R&D spend away from foreign competitors.
Persistent cash burn and a heavy debt load create significant refinancing risks under a higher-for-longer interest rate environment.
Sharp divergence exists between bulls focusing on software-like operating leverage and bears highlighting capital-intensive diagnostic lab realities.
Achieving positive free cash flow remains the critical catalyst to eliminate dilution fears and trigger institutional re-rating.
Strategic risk includes potential regulatory data privacy crackdowns or technological commoditization by generalized foundation models.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Tempus AI, Inc. Common Stock quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Tempus AI, Inc. Common Stock.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$48.22	$57.56	$69.31	$736.09
Quarter 2+6M	Jan 02, 2027	$40.98	$58.29	$74.86	$724.14
Quarter 3+9M	Apr 02, 2027	$34.84	$59.96	$82.34	$713.57
Quarter 4+1Y	Jul 02, 2027	$29.61	$60.85	$78.22	$723.38
Quarter 5+15M	Oct 02, 2027	$27.59	$61.92	$87.61	$716.61
Quarter 6+18M	Jan 02, 2028	$22.62	$66.39	$100.75	$738.34
Quarter 7+21M	Apr 02, 2028	$23.76	$69.82	$108.81	$746.91
Quarter 8+2Y	Jul 02, 2028	$24.71	$71.36	$100.11	$771.93
Quarter 9+27M	Oct 02, 2028	$18.53	$74.01	$110.12	$782.73
Quarter 10+30M	Jan 02, 2029	$21.31	$80.42	$126.64	$807.31
Quarter 11+33M	Apr 02, 2029	$19.18	$84.36	$139.30	$822.72
Quarter 12+3Y	Jul 02, 2029	$20.71	$86.72	$146.26	$846.10
Quarter 13+39M	Oct 02, 2029	$21.13	$89.87	$137.49	$852.53
Quarter 14+42M	Jan 02, 2030	$22.18	$96.62	$156.71	$882.91
Quarter 15+45M	Apr 02, 2030	$21.07	$100.72	$166.31	$900.46
Quarter 16+4Y	Jul 02, 2030	$21.49	$104.89	$174.62	$922.67
Quarter 17+51M	Oct 02, 2030	$20.85	$104.95	$183.66	$935.91
Quarter 18+54M	Jan 02, 2031	$22.10	$112.55	$198.35	$952.30
Quarter 19+57M	Apr 02, 2031	$22.10	$117.22	$208.27	$976.28
Quarter 20+5Y	Jul 02, 2031	$22.10	$123.48	$220.76	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the market's misclassification of the company's business model and strategic moat. While the crowd evaluates the asset either as a standard diagnostic lab or a cyclical software stock vulnerable to macro headwinds, the variant perception recognizes that the physical diagnostics division is actually a subsidized customer acquisition funnel designed to build an unassailable, multi-modal clinical dataset. This proprietary data is structurally insulated from economic downturns and heavily protected by domestic policy mandates like the BIOSECURE Act. As US pharmaceutical companies are forced to onshore their data pipelines, this dataset transitions from a discretionary tool to a mandatory national security asset. The market is mispricing the inevitability of the operating leverage that will occur when high-margin data licensing outpaces physical lab costs.

Advisor Disagreement

The primary disagreement across reports centers on the valuation multiple and the timeline to profitability. Bullish perspectives emphasize the rapid growth of the high-margin data segment and argue that operating leverage will quickly extinguish the cash burn, justifying a premium software multiple. Conversely, bearish reports focus on the capital-intensive nature of the physical diagnostic labs, arguing that the business is being mispriced as a SaaS company. There is also significant debate regarding the severity of regulatory privacy liabilities and whether insider selling signals structural weakness or routine diversification.

Financial Reviews by iPulse AI

Earnings and financials

The company is experiencing explosive sales growth, with annual revenues climbing rapidly, driven by its high-margin data and software segment. However, its bottom-line profits remain deeply negative, with substantial net losses and ongoing cash burn. Analysts agree that the company's future depends on its ability to transition from a cash-burning business to a self-sustaining, profitable enterprise. The main point of disagreement is how quickly this transition will happen. Optimistic views suggest that as the high-margin software business grows, it will easily cover the fixed costs of the physical testing labs, leading to profitability by 2028. Skeptics, however, warn that the heavy costs of running physical laboratories and high stock-based compensation will keep the company unprofitable for much longer, making the stock highly risky in a high-interest-rate environment where investors demand real earnings over future promises.

Profitability and margins

The company's profit margins show a striking contrast between its raw product costs and its overall business expenses. Gross margins, which measure the basic profitability of its services, have expanded beautifully to around seventy percent. This indicates that the core data-licensing business is highly profitable and has strong pricing power. However, operating and net margins remain deeply negative because of massive spending on research, sales, and executive stock compensation. The consensus is that margins will improve as high-margin software sales become a larger part of the business. However, opinions clash on whether the company can trim its heavy overhead costs. Bulls believe operating margins will turn positive within a few years as the business scales, while bears argue that the high costs of running physical labs and generous executive pay will permanently weigh down profitability, making the current high valuation hard to justify.

Balance sheet and leverage

The company's balance sheet presents a mix of near-term safety and long-term risk. On the positive side, it holds a substantial cash cushion of over six hundred million dollars, which provides a temporary buffer to fund its ongoing operations. However, the company also carries a massive debt load of over one billion dollars, resulting in a very high debt-to-equity ratio. Analysts agree that this heavy leverage makes the company highly vulnerable. If the company cannot stop burning cash before its current reserves run out, it will be forced to borrow more money at high interest rates or issue new shares, which would dilute the value of existing investments. While some believe the cash buffer is plenty of runway to reach profitability, others view the high debt as a ticking clock that leaves no room for operational mistakes or economic downturns.

Capex and investment intensity

The company requires heavy spending to build and maintain its competitive edge, but the nature of this spending is a point of debate. On one hand, it operates physical, high-tech laboratories and invests heavily in research and development to gather and organize patient data. Optimists view this heavy upfront spending as a smart, long-term investment that builds an unassailable database, which can eventually be licensed to drug companies at almost zero ongoing cost. They note that capital spending as a percentage of revenue is actually declining, showing increased efficiency. On the other hand, critics argue that this high investment intensity is a permanent burden rather than a one-time cost. They warn that keeping up with rapid advancements in artificial intelligence and genetic sequencing will force the company to continuously spend massive amounts on technology, draining cash and delaying the timeline to positive cash flow.